{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:51Z","timestamp":1740144111802,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Urology research center, Guilan University of Medical Science, Rasht, Iran.","award":["707\/13.4.1395"],"award-info":[{"award-number":["707\/13.4.1395"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2744-y","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T01:14:48Z","timestamp":1530148488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Gholamreza","family":"Mokhtari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-9282","authenticated-orcid":false,"given":"Mojtaba","family":"Teimoori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"2744_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semnephrol.2016.05.008","volume":"36","author":"V Wang","year":"2016","unstructured":"Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36:319\u201330.","journal-title":"Semin Nephrol"},{"key":"2744_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41100-016-0021-7","volume":"2","author":"JB Wetmore","year":"2016","unstructured":"Wetmore JB, Collins AJ. Global challenges posed by the growth of end-stage renal disease. Ren Replace Ther. 2016;2:15.","journal-title":"Ren Replace Ther"},{"issue":"Suppl 2","key":"2744_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.13195","volume":"15","author":"AJ Matas","year":"2015","unstructured":"Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, et al. OPTN\/SRTR 2013 annual data report: kidney. Am J Transplant. 2015;15(Suppl 2):1\u201334.","journal-title":"Am J Transplant"},{"key":"2744_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jac\/28.6.787","volume":"28","author":"HA Kirst","year":"1991","unstructured":"Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother. 1991;28:787\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"2744_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1128\/AAC.33.9.1419","volume":"33","author":"HA Kirst","year":"1989","unstructured":"Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989;33:1419\u201322.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jac\/24.5.765","volume":"24","author":"ML Villa","year":"1989","unstructured":"Villa ML, Valenti F, Scaglione F, Falchi M, Fraschini F. In-vivo and in-vitro interference of antibiotics with antigen-specific antibody responses: effect of josamycin. J Antimicrob Chemother. 1989;24:765\u201374.","journal-title":"J Antimicrob Chemother"},{"key":"2744_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1128\/AAC.40.1.75","volume":"40","author":"A Wildfeuer","year":"1996","unstructured":"Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother. 1996;40:75\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2744_CR8","first-page":"7","volume":"104","author":"P Solidoro","year":"2013","unstructured":"Solidoro P, Braido F, Boffini M, Corsico AG. New life for macrolides. Minerva Med. 2013;104:7\u201314.","journal-title":"Minerva Med"},{"issue":"Suppl A","key":"2744_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","volume":"25","author":"G Foulds","year":"1990","unstructured":"Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73\u201382.","journal-title":"J Antimicrob Chemother"},{"key":"2744_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12967-016-0916-7","volume":"14","author":"G Stallone","year":"2016","unstructured":"Stallone G, Infante B, Di Lorenzo A, Rascio F, Zaza G, Grandaliano G. mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med. 2016;14:152.","journal-title":"J Transl Med"},{"key":"2744_CR11","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/srep07438","volume":"4","author":"F Ratzinger","year":"2014","unstructured":"Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S, et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep. 2014;4:7438.","journal-title":"Sci Rep"},{"key":"2744_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jcf.2013.08.007","volume":"13","author":"TJ Cory","year":"2014","unstructured":"Cory TJ, Birket SE, Murphy BS, Hayes D Jr, Anstead MI, Kanga JF, et al. Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros. 2014;13:164\u201371.","journal-title":"J Cyst Fibros"},{"issue":"Suppl B","key":"2744_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/41.suppl_2.47","volume":"41","author":"F Scaglione","year":"1998","unstructured":"Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother. 1998;41(Suppl B):47\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"2744_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2249.2007.03299.x","volume":"147","author":"K Sugiyama","year":"2007","unstructured":"Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T, Sakamoto N, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol. 2007;147:540\u20136.","journal-title":"Clin Exp Immunol"},{"key":"2744_CR15","first-page":"397","volume":"141","author":"RM Strieter","year":"1992","unstructured":"Strieter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, Becker FS, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol. 1992;141:397\u2013407.","journal-title":"Am J Pathol"},{"key":"2744_CR16","doi-asserted-by":"publisher","first-page":"L75","DOI":"10.1152\/ajplung.00093.2005","volume":"290","author":"M Shinkai","year":"2006","unstructured":"Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:L75\u201385.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2744_CR17","doi-asserted-by":"publisher","first-page":"e82687","DOI":"10.1371\/journal.pone.0082687","volume":"8","author":"K Wacker","year":"2013","unstructured":"Wacker K, Denker S, Hildebrand A, Eberwein P, Reinhard T, Schwartzkopff J. Short-term azithromycin treatment promotes cornea allograft survival in the rat. PLoS One. 2013;8:e82687.","journal-title":"PLoS One"},{"key":"2744_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/ICO.0b013e318274a690","volume":"32","author":"CA Medina","year":"2013","unstructured":"Medina CA, Rowe AM, Yun H, Knickelbein JE, Lathrop KL, Hendricks RL. Azithromycin (AZM) treatment increases survival of high-risk corneal allotransplants. Cornea. 2013;32:658\u201366.","journal-title":"Cornea"},{"key":"2744_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/cei.12023","volume":"171","author":"S Iwamoto","year":"2013","unstructured":"Iwamoto S, Azuma E, Kumamoto T, Hirayama M, Yoshida T, Ito M, et al. Efficacy of azithromycin in preventing lethal graft-versus-host disease. Clin Exp Immunol. 2013;171:338\u201345.","journal-title":"Clin Exp Immunol"},{"key":"2744_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/nur.20247","volume":"31","author":"MA Hertzog","year":"2008","unstructured":"Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31:180\u201391.","journal-title":"Res Nurs Health"},{"key":"2744_CR21","unstructured":"Dallal GE. Randomization.com . 2016."},{"key":"2744_CR22","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2146\/ajhp080155","volume":"65","author":"NT Williams","year":"2008","unstructured":"Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65:2347\u201357.","journal-title":"Am J Health Syst Pharm"},{"key":"2744_CR23","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2146\/ajhp080632","volume":"66","author":"PD Wohlt","year":"2009","unstructured":"Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009;66:1458\u201367.","journal-title":"Am J Health Syst Pharm"},{"key":"2744_CR24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/CDLI.7.6.925-931.2000","volume":"7","author":"LW Chow","year":"2000","unstructured":"Chow LW, Yuen KY, Woo PC, Wei WI. Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clin Diagn Lab Immunol. 2000;7:925\u201331.","journal-title":"Clin Diagn Lab Immunol"},{"key":"2744_CR25","unstructured":"Eremenko AA, Chernova EV, Vinnitskii LI, Buniatian KA, Inviiaeva EV, Bogomolova NS, et al. Effect of clarithromycin on the systemic inflammatory response syndrome severity in patients after myocardial revascularization surgery. Anesteziol Reanimatol. 2012;3:67\u201371."},{"key":"2744_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3892\/etm.2014.2120","volume":"9","author":"ZG Xu","year":"2015","unstructured":"Xu ZG, Gao Y, He JG, Xu WF, Jiang M, Jin HS. Effects of azithromycin on Pseudomonas aeruginosa isolates from catheter-associated urinary tract infection. Exp Ther Med. 2015;9:569\u201372.","journal-title":"Exp Ther Med"},{"key":"2744_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijantimicag.2014.11.008","volume":"45","author":"H Saini","year":"2015","unstructured":"Saini H, Chhibber S, Harjai K. Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections. Int J Antimicrob Agents. 2015;45:359\u201367.","journal-title":"Int J Antimicrob Agents"},{"key":"2744_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.18773\/austprescr.2015.030","volume":"38","author":"BJ McMullan","year":"2015","unstructured":"McMullan BJ, Mostaghim M. Prescribing azithromycin. Aust Prescr. 2015;38:87\u20139.","journal-title":"Aust Prescr"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2744-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T13:41:47Z","timestamp":1604497307000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2744"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2744-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants who meet the inclusion criteria will be asked to sign the informed consent form. The study protocol has already been approved by the Guilan Medical University Ethics Review Committee (approval identifier: IR. GUMS.REC1395.105).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"345"}}